TEST:

LAG-3 IHC assay

The LAG-3 IHC assay is for the use in a clinical trial studying dual checkpoint inhibitors that included a LAG-3 immunotherapy. The assay will enable the analysis of LAG-3 status in the tumor and the correlation between expression status and response to LAG-3 immunotherapy. This assay is also being used in other ongoing clinical trials evaluating clinical response to LAG-3-directed cancer treatments. The test is available for use in both clinical trials and for the care and treatment of patients.